The rising burden of chronic diseases worldwide is driving life sciences companies’ drug development efforts. These drug development efforts need to abide by the strict drug safety regulations of public health organizations, such as the US Federal Drug Administration (FDA) and the European Medicines Agency (EMA). The regulatory protocols mandate the prior- and post-marketing safety assessment of drugs and are increasingly pressing biopharma and medical device companies to effectively capture, assess, and monitor Adverse Events (AEs) to gain the trust of both regulators and consumers.
In this viewpoint, we focus on the challenges that face the US$19 billion Pharmacovigilance (PV) market amid increasing AEs and changing regulations. We also look at the measures that life sciences enterprises have adopted in tackling these challenges, including partnering with third-party providers for technology solutions.
Industry
Life Sciences BPS
Geography
Global
Contents
This report provides a detailed analysis of the PV landscape, including:
The COVID-19 outbreak compelled the life sciences industry to innovate and transform digitally. However, the current global macroeconomic and socio-political uncertainty, coupled with increasing research and development IT expenditure, have created…
